SageView Advisory Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

SageView Advisory Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$11.7K	Buy	+69	New	+$10.6K	﹤0.01%	1656

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SageView Advisory Group's JAZZ Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Jazz Pharmaceuticals (JAZZ) in Q4 2025: 69 shares worth $11.7K. The stake represents ﹤0.01% of the portfolio and ranks #1656 among its holdings.

573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

SageView Advisory Group held 69 shares of Jazz Pharmaceuticals worth $11.7K as of Q4 2025.
Jazz Pharmaceuticals was a new SageView Advisory Group position in Q4 2025.
Jazz Pharmaceuticals made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #1656 holding.
573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.